tiprankstipranks
Trending News
More News >

Grifols Exceeds Q1 2025 Forecasts with Strong Revenue and Profit Growth

Story Highlights
Grifols Exceeds Q1 2025 Forecasts with Strong Revenue and Profit Growth

Confident Investing Starts Here:

An update from Grifols ( (ES:GRF) ) is now available.

Grifols reported a strong financial performance in the first quarter of 2025, exceeding forecasts with a 7.4% increase in revenues and a 14.2% rise in adjusted EBITDA. The company’s strategic execution and robust demand in the Biopharma sector contributed to a 179% growth in net profit and improved free cash flow by 209 million euros. Despite a temporary dip in albumin sales due to license renewal in China, Grifols maintained a solid liquidity position and reduced its leverage ratio, positioning itself for sustained growth in 2025.

The most recent analyst rating on (ES:GRF) stock is a Buy with a EUR22.00 price target. To see the full list of analyst forecasts on Grifols stock, see the ES:GRF Stock Forecast page.

More about Grifols

Grifols is a global leader in the healthcare sector, specializing in plasma-derived medicines. The company focuses on biopharmaceuticals and diagnostics, with a significant presence in immunoglobulin and other specialty proteins. Grifols operates with a strong local presence in its main markets, maintaining self-sufficient and vertically integrated regional plasma ecosystems.

YTD Price Performance: -11.13%

Average Trading Volume: 2,560,265

Technical Sentiment Signal: Sell

Current Market Cap: €5.06B

See more data about GRF stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App